SCHEMBL19260908

SCHEMBL19260908

[CH2]Cc1ccccc1SCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.59
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTPRC P08575 1/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 2/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
LMNA P02545 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2045886 0.81 POLB (0.52) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL9507471 0.81 POLB (0.61) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL1902909 0.79 POLB (0.59) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL21315691 0.79 POLB (0.64) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL1903485 0.79 APOBEC3G (0.59) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL6638095 0.79 POLB (0.59) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL3027067 0.77 HPGD (0.36) POLBHSD17B10KMT2AL3MBTL1HTT
SCHEMBL2929900 0.77 POLB (0.61) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL3887461 0.76 POLB (0.55) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL14691235 0.76 POLB (0.55) POLBHSD17B10KMT2AL3MBTL1PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4322945-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2024-02-21 EP disclosed
EP-4284370-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2023-12-06 EP disclosed
EP-4110333-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-01-04 EP disclosed
EP-3880208-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-09-22 EP disclosed
EP-3849537-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-07-21 EP disclosed
WO-2021061749-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2021-04-01 WO disclosed
EP-3746446-A1 PRC2 INHIBITORS Mirati Therapeutics, Inc. (US) 2020-12-09 EP disclosed
WO-2020167952-A1 MAT2A INHIBITORS Mirati Therapeutics, Inc. (US) 2020-08-20 WO disclosed
WO-2020101736-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-05-22 WO disclosed
WO-2020055758-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 WO disclosed
WO-2019152419-A1 PRC2 INHIBITORS MIRATI THERAPEUTICS, INC (US) 2019-08-08 WO disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 EP disclosed
WO-2017214413-A1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Chrysalis, Inc. (US) 2017-12-14 WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 WO disclosed
WO-2017143011-A1 HISTONE DEMETHYLASE INHIBITORS Chrysalis, Inc. (US) 2017-08-24 WO disclosed